SummaryAvalere was recently commissioned to project how policy proposals related to biosimilars would impact government spending and patient costs, including modeling and scoring analyses created for 3 proposals publicly released by the Biosimilars Forum in May 2019.
Avalere continues to stand firmly behind analyses made public by our clients. All analyses are conducted independently from each other, using differing sets of unique assumptions and are not directly comparable. It is also important to clarify that Avalere did not share confidential client information as part of any biosimilar-related analyses. Please refer further questions about the analyses to the associated customer.
produces measurable results. Let's work together.